Antidote
SEPTEMBER 30, 2022
Since 1999, October has been recognized as Health Literacy Month. The goal, as defined by the Institute for Healthcare Advancement , is to raise awareness about the importance of understandable health information — but what is health literacy and why is it important?
Drug Patent Watch
SEPTEMBER 27, 2022
This chart shows the drugs with the most patents in Ukraine. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Ukraine? appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
SEPTEMBER 28, 2022
Autumn is here! Please savor these Drug Channels acorns that we’ve squirrelled away for you: One patient’s troubling experience with SaveonSP PBMs ramp up formulary exclusions for oncology drugs The mega-players dominating Medicare Advantage My 340B FOIA efforts yield change at HRSA! Plus, two new resources from Drug Channels Institute. P.S. Join my 32,000 LinkedIn followers for daily links to neat stuff.
Eye on FDA
SEPTEMBER 28, 2022
FDA published notice recently that the Office of Prescription Drug Promotion (OPDP) was proposing some new research related to the promotion of medicines by pharmaceutical companies. The research was new (kind of) but the direction was more of the same old focus – direct-to-consumer advertising (DTC). First, just a note on why the research is of importance at all.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Advarra
SEPTEMBER 30, 2022
Is the clinical research industry winning or failing at innovation? It probably depends on who you ask and likely full of nuance. In the past decade, trials have evolved to include not just traditional drugs and medical devices, but also innovations like cell and gene therapies, wearables, and more. As exciting as that growth may be, it invites more complexity.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Antidote
SEPTEMBER 29, 2022
Though it has only been identified since the early 1990s, Eosinophilic Esophagitis (EoE) has come to be known as a major cause of gastrointestinal illness. Though there are still a lot of unknowns surrounding EoE, ongoing research hopes to provide patients and medical professionals with more insights in the future.
NIH Director's Blog: Drug Development
SEPTEMBER 27, 2022
Wearable electronic sensors hold tremendous promise for improving human health and wellness. That promise already runs the gamut from real-time monitoring of blood pressure and abnormal heart rhythms to measuring alcohol consumption and even administering vaccines. Now a new study published in the journal Science Advances [1] demonstrates the promise of wearables also extends to the laboratory.
Advarra
SEPTEMBER 29, 2022
Informed consent is one of the central protections the regulations provide to research subjects. This tip sheet outlines the regulatory requirements for research informed consent forms (ICFs). The regulatory requirements for informed consent will vary depending upon which regulations apply to the conduct of a particular study. Note: Individual institutional review boards (IRBs) may have their own specific policies regarding how ICFs should be formatted, how to address certain regulatory criteri
Drug Patent Watch
SEPTEMBER 30, 2022
This chart shows the pharmaceutical companies with the most aerosol dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most aerosol dosed drugs…. The post Which pharmaceutical companies have the most aerosol dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
National Institute on Drug Abuse: Nora's Blog
SEPTEMBER 27, 2022
Supporting Needed Research on Recovery mfleming Tue, 09/27/2022 - 13:33 Nora's Blog September 28, 2022 National Recovery Month (Recovery Month), which started in 1989, is a national observance held every September to promote and support new evidence-based treatment and recovery practices, the nation’s strong and proud recovery community, and the dedication of service providers and communities who make recovery in all its forms possible.
Antidote
SEPTEMBER 26, 2022
At Antidote, we believe that getting to know patients is about more than making an initial connection. As a digital patient engagement company with a database of 400,000 users, we know a lot about finding patients — but we also know how to keep them engaged.
Drug & Device Law
SEPTEMBER 29, 2022
The decision we report on today, Frye v. Novartis Pharms. Corp., 2022 WL 4305656 (E.D. Ark. 2022), leaves us shaking our heads. The court denied the defendant’s motion to dismiss, which was based on preemption and other grounds. In the course of denying the motion, the court misconstrued the law at least once and possibly twice. Frye involves a biologic designed to treat Neovascular Age-Related Macular Degeneration.
Drug Patent Watch
SEPTEMBER 29, 2022
Annual Drug Patent Expirations for LUMAKRAS Lumakras is a drug marketed by Amgen Inc and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Amgen Inc drug LUMAKRAS appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
SEPTEMBER 29, 2022
Annual Drug Patent Expirations for NOCTIVA Noctiva is a drug marketed by Serenity Pharms Llc and is included in one NDA. There are two patents protecting this drug. Drug patent…. The post New patent for Serenity Pharms drug NOCTIVA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 28, 2022
This chart shows the pharmaceutical companies with the most liquid dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most liquid dosed drugs…. The post Which pharmaceutical companies have the most liquid dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 28, 2022
Annual Drug Patent Expirations for CLARINEX+D+24+HOUR Clarinex D 24 Hour is a drug marketed by Organon and is included in one NDA. There are two patents protecting this drug. This…. The post New patent expiration for Organon drug CLARINEX D 24 HOUR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 28, 2022
Annual Drug Patent Expirations for ORKAMBI Orkambi is a drug marketed by Vertex Pharms Inc and is included in two NDAs. It is available from one supplier. There are twenty…. The post New patent for Vertex Pharms drug ORKAMBI appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
SEPTEMBER 28, 2022
Annual Drug Patent Expirations for TRIKAFTA+%28COPACKAGED%29 Trikafta (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Vertex Pharms drug TRIKAFTA (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 27, 2022
Annual Drug Patent Expirations for MYRBETRIQ+GRANULES Myrbetriq Granules is a drug marketed by Apgdi and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent expiration for APGDI drug MYRBETRIQ GRANULES appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 27, 2022
Annual Drug Patent Expirations for MYRBETRIQ Myrbetriq is a drug marketed by Apgdi and is included in two NDAs. It is available from three suppliers. There are eight patents protecting…. The post New patent expiration for APGDI drug MYRBETRIQ appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 27, 2022
Annual Drug Patent Expirations for LYNPARZA Lynparza is a drug marketed by Astrazeneca and is included in two NDAs. It is available from one supplier. There are eleven patents protecting…. The post New patent for Astrazeneca drug LYNPARZA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
SEPTEMBER 27, 2022
Annual Drug Patent Expirations for TAUVID Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. It is available from one supplier. There is one…. The post New patent for Avid Radiopharms drug TAUVID appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 26, 2022
This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 25, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 25, 2022
Annual Drug Patent Expirations for ABILIFY Abilify is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in six NDAs. It is available from one supplier.…. The post New patent expiration for Otsuka drug ABILIFY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
SEPTEMBER 25, 2022
Annual Drug Patent Expirations for ABILIFY+MAINTENA+KIT Abilify Maintena Kit is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. It is available from one supplier.…. The post New patent expiration for Otsuka Pharm drug ABILIFY MAINTENA KIT appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
98 
Let's personalize your content